Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors

Ching Chuan Kuo, Tsang Wu, Li Tzong Chen, Her Shyong Shiah, Ching Ming Wu, Yen Ting Cheng, Wen Yu Pan, Jin Fen Liu, Kuo Li Chen, Yun Ning Yang, Shan Na Chen, Jang Yang Chang

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Arsenic trioxide (As 2O 3) is an effective treatment for relapsed or refractory acute promyelocytic leukemia (APL). After the discovery of As 2O 3 as a promising treatment for APL, several studies investigated the use of As 2O 3 as a single agent in the treatment of solid tumors; however, its therapeutic efficacy is limited. Thus, the systematic study of the combination of As 2O 3 with other clinically used chemotherapeutic drugs to improve its therapeutic efficacy in treating human solid tumors is merited. In this study, we demonstrate for the first time, using isobologram analysis, that As 2O 3 exhibits a synergistic interaction with N,N′-bis(2-chloroethyl)-N-nitrosourea (BCNU). The synergistic augmentation of the cytotoxicity of As 2O 3 with BCNU is in part through the autophagic cell death machinery in human solid tumor cells. As 2O 3 and BCNU in combination produce enhanced cytotoxicity via the depletion of reduced glutathione (GSH) and augmentation of reaction oxygen species (ROS) production. Further analysis indicated that the extension of GSH depletion by this combined regimen occurs through the inhibition of the catalytic activity of glutathione reductase. Blocking ROS production with antioxidants or ROS scavengers effectively inhibits cell death and autophagy formation, indicating that redox-mediated autophagic cell death involves the synergism of As 2O 3 with BCNU. Taken together, this is the first evidence that BCNU could help to extend the therapeutic spectrum of As 2O 3. These findings will be useful in designing future clinical trials of combination chemotherapy with As 2O 3 and BCNU, with the potential for broad use against a variety of solid tumors.

Original languageEnglish
Pages (from-to)2195-2209
Number of pages15
JournalFree Radical Biology and Medicine
Volume51
Issue number12
DOIs
Publication statusPublished - Dec 15 2011
Externally publishedYes

Fingerprint

Carmustine
Autophagy
Cell death
Oxidation-Reduction
Tumors
Neoplasms
Acute Promyelocytic Leukemia
Cytotoxicity
Oxygen
Therapeutics
Chemotherapy
Glutathione Reductase
Combination Drug Therapy
Refractory materials
Machinery
Glutathione
arsenic trioxide
Catalyst activity
Cell Death
Antioxidants

Keywords

  • Arsenic trioxide
  • Autophagy
  • BCNU
  • Cancer therapy
  • Free radicals
  • Redox
  • Synergism

ASJC Scopus subject areas

  • Biochemistry
  • Physiology (medical)

Cite this

Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors. / Kuo, Ching Chuan; Wu, Tsang; Chen, Li Tzong; Shiah, Her Shyong; Wu, Ching Ming; Cheng, Yen Ting; Pan, Wen Yu; Liu, Jin Fen; Chen, Kuo Li; Yang, Yun Ning; Chen, Shan Na; Chang, Jang Yang.

In: Free Radical Biology and Medicine, Vol. 51, No. 12, 15.12.2011, p. 2195-2209.

Research output: Contribution to journalArticle

Kuo, CC, Wu, T, Chen, LT, Shiah, HS, Wu, CM, Cheng, YT, Pan, WY, Liu, JF, Chen, KL, Yang, YN, Chen, SN & Chang, JY 2011, 'Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors', Free Radical Biology and Medicine, vol. 51, no. 12, pp. 2195-2209. https://doi.org/10.1016/j.freeradbiomed.2011.09.023
Kuo, Ching Chuan ; Wu, Tsang ; Chen, Li Tzong ; Shiah, Her Shyong ; Wu, Ching Ming ; Cheng, Yen Ting ; Pan, Wen Yu ; Liu, Jin Fen ; Chen, Kuo Li ; Yang, Yun Ning ; Chen, Shan Na ; Chang, Jang Yang. / Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors. In: Free Radical Biology and Medicine. 2011 ; Vol. 51, No. 12. pp. 2195-2209.
@article{acbc98475fd147aa962fb0241e9c9dd0,
title = "Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors",
abstract = "Arsenic trioxide (As 2O 3) is an effective treatment for relapsed or refractory acute promyelocytic leukemia (APL). After the discovery of As 2O 3 as a promising treatment for APL, several studies investigated the use of As 2O 3 as a single agent in the treatment of solid tumors; however, its therapeutic efficacy is limited. Thus, the systematic study of the combination of As 2O 3 with other clinically used chemotherapeutic drugs to improve its therapeutic efficacy in treating human solid tumors is merited. In this study, we demonstrate for the first time, using isobologram analysis, that As 2O 3 exhibits a synergistic interaction with N,N′-bis(2-chloroethyl)-N-nitrosourea (BCNU). The synergistic augmentation of the cytotoxicity of As 2O 3 with BCNU is in part through the autophagic cell death machinery in human solid tumor cells. As 2O 3 and BCNU in combination produce enhanced cytotoxicity via the depletion of reduced glutathione (GSH) and augmentation of reaction oxygen species (ROS) production. Further analysis indicated that the extension of GSH depletion by this combined regimen occurs through the inhibition of the catalytic activity of glutathione reductase. Blocking ROS production with antioxidants or ROS scavengers effectively inhibits cell death and autophagy formation, indicating that redox-mediated autophagic cell death involves the synergism of As 2O 3 with BCNU. Taken together, this is the first evidence that BCNU could help to extend the therapeutic spectrum of As 2O 3. These findings will be useful in designing future clinical trials of combination chemotherapy with As 2O 3 and BCNU, with the potential for broad use against a variety of solid tumors.",
keywords = "Arsenic trioxide, Autophagy, BCNU, Cancer therapy, Free radicals, Redox, Synergism",
author = "Kuo, {Ching Chuan} and Tsang Wu and Chen, {Li Tzong} and Shiah, {Her Shyong} and Wu, {Ching Ming} and Cheng, {Yen Ting} and Pan, {Wen Yu} and Liu, {Jin Fen} and Chen, {Kuo Li} and Yang, {Yun Ning} and Chen, {Shan Na} and Chang, {Jang Yang}",
year = "2011",
month = "12",
day = "15",
doi = "10.1016/j.freeradbiomed.2011.09.023",
language = "English",
volume = "51",
pages = "2195--2209",
journal = "Free Radical Biology and Medicine",
issn = "0891-5849",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors

AU - Kuo, Ching Chuan

AU - Wu, Tsang

AU - Chen, Li Tzong

AU - Shiah, Her Shyong

AU - Wu, Ching Ming

AU - Cheng, Yen Ting

AU - Pan, Wen Yu

AU - Liu, Jin Fen

AU - Chen, Kuo Li

AU - Yang, Yun Ning

AU - Chen, Shan Na

AU - Chang, Jang Yang

PY - 2011/12/15

Y1 - 2011/12/15

N2 - Arsenic trioxide (As 2O 3) is an effective treatment for relapsed or refractory acute promyelocytic leukemia (APL). After the discovery of As 2O 3 as a promising treatment for APL, several studies investigated the use of As 2O 3 as a single agent in the treatment of solid tumors; however, its therapeutic efficacy is limited. Thus, the systematic study of the combination of As 2O 3 with other clinically used chemotherapeutic drugs to improve its therapeutic efficacy in treating human solid tumors is merited. In this study, we demonstrate for the first time, using isobologram analysis, that As 2O 3 exhibits a synergistic interaction with N,N′-bis(2-chloroethyl)-N-nitrosourea (BCNU). The synergistic augmentation of the cytotoxicity of As 2O 3 with BCNU is in part through the autophagic cell death machinery in human solid tumor cells. As 2O 3 and BCNU in combination produce enhanced cytotoxicity via the depletion of reduced glutathione (GSH) and augmentation of reaction oxygen species (ROS) production. Further analysis indicated that the extension of GSH depletion by this combined regimen occurs through the inhibition of the catalytic activity of glutathione reductase. Blocking ROS production with antioxidants or ROS scavengers effectively inhibits cell death and autophagy formation, indicating that redox-mediated autophagic cell death involves the synergism of As 2O 3 with BCNU. Taken together, this is the first evidence that BCNU could help to extend the therapeutic spectrum of As 2O 3. These findings will be useful in designing future clinical trials of combination chemotherapy with As 2O 3 and BCNU, with the potential for broad use against a variety of solid tumors.

AB - Arsenic trioxide (As 2O 3) is an effective treatment for relapsed or refractory acute promyelocytic leukemia (APL). After the discovery of As 2O 3 as a promising treatment for APL, several studies investigated the use of As 2O 3 as a single agent in the treatment of solid tumors; however, its therapeutic efficacy is limited. Thus, the systematic study of the combination of As 2O 3 with other clinically used chemotherapeutic drugs to improve its therapeutic efficacy in treating human solid tumors is merited. In this study, we demonstrate for the first time, using isobologram analysis, that As 2O 3 exhibits a synergistic interaction with N,N′-bis(2-chloroethyl)-N-nitrosourea (BCNU). The synergistic augmentation of the cytotoxicity of As 2O 3 with BCNU is in part through the autophagic cell death machinery in human solid tumor cells. As 2O 3 and BCNU in combination produce enhanced cytotoxicity via the depletion of reduced glutathione (GSH) and augmentation of reaction oxygen species (ROS) production. Further analysis indicated that the extension of GSH depletion by this combined regimen occurs through the inhibition of the catalytic activity of glutathione reductase. Blocking ROS production with antioxidants or ROS scavengers effectively inhibits cell death and autophagy formation, indicating that redox-mediated autophagic cell death involves the synergism of As 2O 3 with BCNU. Taken together, this is the first evidence that BCNU could help to extend the therapeutic spectrum of As 2O 3. These findings will be useful in designing future clinical trials of combination chemotherapy with As 2O 3 and BCNU, with the potential for broad use against a variety of solid tumors.

KW - Arsenic trioxide

KW - Autophagy

KW - BCNU

KW - Cancer therapy

KW - Free radicals

KW - Redox

KW - Synergism

UR - http://www.scopus.com/inward/record.url?scp=81855176014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81855176014&partnerID=8YFLogxK

U2 - 10.1016/j.freeradbiomed.2011.09.023

DO - 10.1016/j.freeradbiomed.2011.09.023

M3 - Article

C2 - 22001324

AN - SCOPUS:81855176014

VL - 51

SP - 2195

EP - 2209

JO - Free Radical Biology and Medicine

JF - Free Radical Biology and Medicine

SN - 0891-5849

IS - 12

ER -